New Liver Disease Treatment Device Unveiled
新型肝臟疾病治療裝置問世
In April 2026, BD announced a significant milestone with its Liverty™ TIPS Stent Graft, a device designed to manage complications of cirrhosis and portal hypertension.
2026年4月，BD公司宣布其Liverty™ TIPS支架移植體達成了一項重要的里程碑。
Meanwhile, innovations like miroliverELAP®—a bioengineered liver support system—are targeting acute liver failure.
這款可調式支架有助於降低危險的血壓，從而改善病患的預後。
Other advancements include non-invasive histotripsy for tumors and promising cell-based therapies like those explored in the MATCH trial.
與此同時，像 miroliverELAP®（一種生物工程肝臟支援系統）這樣的創新技術，正針對急性肝衰竭進行治療。
It is important to distinguish between these technologies: the Liverty™ device provides mechanical support for chronic cirrhosis, while miroliverELAP® offers regenerative assistance for sudden failure.
其他進展還包括針對腫瘤的非侵入式組織碎裂術，以及像 MATCH試驗中所探索的基於細胞的療法。
Together, these tools represent a major leap in modern hepatology.
區分這些技術至關重要：Liverty™設備為慢性肝硬化提供機械支援，而miroliverELAP®則為突發性肝衰竭提供再生協助。
